Results: We were involved in 6 cases of PM/DM with interstitial pneumonia and malignant tumor. PM/DM-related autoantibodies were confirmed in 5 cases. Two cases have anti-transcriptional intermediary factor 1-γ (TIF1-γ) antibody, 2 cases have anti-melanoma differentiationassociated gene 5 (MDA5) antibody, and 1 case has anti-aminoacyl t ribonucleic acid synthetase (ARS) antibody, respectively.
Two cases preceded treatment for malignant tumor, and 4 cases preceded treatment for IP or DM. The reasons that preceded the treatment of IP and DM were subacute exacerbation of IP or severe myositis with early stage of malignant tumor. At the present time, 4 cases are treating malignant tumor, but all cases become exacerbated the symptoms of IP or dermatitis and myositis after malignant tumor treatment. One case died due to IP.
Conclusion:
There is no prescription which treatment should be prioritized for IP or malignant tumor in PM/DM patients. However, there are cases in which the patient dies due to progress of IP even after treatment of the malignant tumor. We should make a decision as a priority to treat in individual case. Methods: This was a prospective, observational study comprising 112 newly diagnosed patients with ILD as per the ATS/ERS statement 2013. These patients were screened for the presence of anxiety and/or depression using the Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression scores (HRSD) respectively. Based on the presence of anxiety and/or depression, these patients were grouped into: Group 1 (Anxiety alone), Group 2 (Depression alone), Group 3 (Anxiety & Depression both) and Group 4 (Neither Anxiety nor Depression). In addition, in these patients, Health Related Quality of Life (HRQoL) was assessed using Short Form-36 (SF-36) questionnaire.
Results: Anxiety was seen in 67/112 (59.8%) and depression in 64/112 (57.1%) patients. The mean HAM-A and HRSD scores were 10.17 + 10.39 and 9.17 + 6.11 respectively. The patients were categorised as follows: Group 1 with 21 (18.75%), Group 2 with 18 (16.07%), Group 3 with 46 (41.07%) and Group 4 with 27 (24.11%). There was a statistically significant difference in HRQoL between the groups (P = 0.000) with the physical component as well as mental component score of SF-36 being worse in Group 3.
Chronic lung diseases such as ILD continue to cause significant morbidity and mortality. The findings in our study indicate that anxiety and depression have higher prevalence in Indian patients with ILD. A number of parameters affect the overall HRQoL in patients with ILD. Recently, both anxiety and depression have been seen to have an impact on HRQoL in ILD. The presence of anxiety/depression significantly influenced patient HRQoL in our study, highlighting the need for improved detection and treatment of such conditions in this patient population. Background and Aims: Combined pulmonary fibrosis and emphysema (CPFE) has been recognized as a unique entity that is characterized by upper lung emphysema and lower lung fibrosis. It was reported that CPFE patients also were in risk to have acute exacerbation, being similar to idiopathic pulmonary fibrosis (IPF) patients. However, there are few reports on the prognosis of acute exacerbation of CPFE (AE-CPFE). The aim of this study is to investigate the clinical prognosis of AE-CPFE.
Methods:
We retrospectively reviewed the medical records of patients in Shinshu University Hospital in Matsumoto, Japan from 2003 to 2017 and identified 23 patients with AE-CPFE and 41 patients with acute exacerbation of IPF (AE-IPF). CPFE were diagnosed with the findings of fibrosis concomitant with usual interstitial pneumonia and more than 7 points of low attenuation area score by high resolution computed tomography.
Results: The mean age of the AE-CPFE was 73.4 years, which was statistically similar to mean age of AE-IPF (71.0 years, P = 0.16). There were no significant differences of the treatments contents and respiratory management for both of before and after exacerbation between the AE-CPFE and AE-IPF. However, the mean serum KL-6 and white blood cell (WBC) counts were significantly lower in the AE-CPFE (KL-6: 1069 U/μL; WBC: 9357/μL) than in the AE-IPF (KL-6: 2130 U/μL, P < 0.001; WBC: 10809/μL, P = 0.029). There was no significant difference of the base line of Gender-Age-Physiology score between the two groups (AE-CPFE: 4.5, AE-IPF: 4.7, P = 0.58). The median survival time was 117.3 days in the AE-CPFE and 68.4 days in the AE-IPF. The Kaplan-Meier curves showed that the survival time was longer in the patients with AE-CPFE than the patients with AE-IPF by log rank test (P = 0.0053).
Conclusion:
The prognosis of AE-CPFE is significantly better than that of AE-IPF. 
